Clinical Observation of Flupentixol and Melitracen Combined with Pregabalin in the Treatment of Painful Diabetic Peripheral Neuropathy
10.6039/j.issn.1001-0408.2016.08.30
- VernacularTitle:氟哌噻吨美利曲辛联合普瑞巴林治疗痛性糖尿病周围神经病变的临床观察
- Author:
Yanping WANG
- Publication Type:Journal Article
- Keywords:
Flupentixol and melitracen;
Pregabalin;
Diabetes;
Peripheral neuropathy
- From:
China Pharmacy
2016;27(8):1104-1106,1107
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe therapeutic efficacy and safety of flupentixol and melitracen combined with pregabalin in the treatment of painful diabetic peripheral neuropathy(PDPN). METHODS:150 cases diagnosed as PDPN were selected and ran-domly divided into control group A,control group B and combination group,with 50 cases in each group. All patients received ba-sic therapy such as the control of blood glucose,blood pressure and blood lipid. Control group A was additionally given mecobala-mine 1 mg added into 0.9% Sodium chloride solution,qd,ivgtt,2 weeks later,given Mecobalamine tablet 0.5 mg,po,tid;con-trol group B was additionally given pregabalin 75 mg,po,bid;combination group was additionally given Flupentixol and melitra-cen tablet,10 mg,bid,on the basis of control group B. 3 groups were given 4 weeks treatment. After treatment,VAS score, HAMD score,and SNCV and MNVC of median nerve and peroneal nerve were compared among 3 groups. Clinical efficacy and ADR were observed. RESULTS:After treatment,VAS score and HAMD score of combination group were significantly lower than control group A and B,with statistical significance(P<0.05). SNCV and MNCV of median nerve and peroneal nerve in combina-tion group were significantly higher than in control group A and B,with statistical significance(P<0.05).The effective rate of com-bination group(90.0%)was significantly higher than that of control group A(56.0%)and B(74.0%),with statistical signifi-cance(P<0.05). No serious ADR was found in 3 groups during treatment. CONCLUSIONS:Flupentixol and melitracen combined with pregabalin have definite therapeutic efficacy in the treatment of PDPN with good safety.
